vs
安霸（AMBA）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是安霸的1.2倍（$127.1M vs $108.5M），安霸同比增速更快（31.2% vs 17.1%），安霸自由现金流更多（$31.4M vs $-26.7M），过去两年安霸的营收复合增速更高（45.0% vs 20.8%）
安霸是美国无晶圆厂半导体设计企业，专注于低功耗高清、超高清视频压缩、图像处理及计算机视觉处理器研发。其芯片产品广泛应用于视频安防、高级驾驶辅助系统、电子后视镜、行车记录仪、驾驶舱内监测、自动驾驶、机器人等多元人机视觉场景。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
AMBA vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.2倍
$108.5M
营收增速更快
AMBA
高出14.1%
17.1%
自由现金流更多
AMBA
多$58.1M
$-26.7M
两年增速更快
AMBA
近两年复合增速
20.8%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $108.5M | $127.1M |
| 净利润 | $-15.1M | — |
| 毛利率 | 59.6% | 51.0% |
| 营业利润率 | -15.0% | -54.6% |
| 净利率 | -13.9% | — |
| 营收同比 | 31.2% | 17.1% |
| 净利润同比 | 37.2% | — |
| 每股收益（稀释后） | $-0.35 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMBAZLAB
| Q4 25 | $108.5M | $127.1M | ||
| Q3 25 | $95.5M | $115.4M | ||
| Q2 25 | $85.9M | $109.1M | ||
| Q1 25 | $84.0M | $105.7M | ||
| Q4 24 | $82.7M | $108.5M | ||
| Q3 24 | $63.7M | $101.8M | ||
| Q2 24 | $54.5M | $100.1M | ||
| Q1 24 | $51.6M | $87.1M |
净利润AMBAZLAB
| Q4 25 | $-15.1M | — | ||
| Q3 25 | $-20.0M | $-36.0M | ||
| Q2 25 | $-24.3M | $-40.7M | ||
| Q1 25 | $-20.2M | $-48.4M | ||
| Q4 24 | $-24.1M | — | ||
| Q3 24 | $-34.9M | $-41.7M | ||
| Q2 24 | $-37.9M | $-80.3M | ||
| Q1 24 | $-60.6M | $-53.5M |
毛利率AMBAZLAB
| Q4 25 | 59.6% | 51.0% | ||
| Q3 25 | 58.9% | 59.5% | ||
| Q2 25 | 60.0% | 60.6% | ||
| Q1 25 | 60.0% | 63.6% | ||
| Q4 24 | 60.6% | 61.5% | ||
| Q3 24 | 60.8% | 64.1% | ||
| Q2 24 | 60.9% | 64.9% | ||
| Q1 24 | 59.8% | 61.4% |
营业利润率AMBAZLAB
| Q4 25 | -15.0% | -54.6% | ||
| Q3 25 | -23.0% | -42.3% | ||
| Q2 25 | -30.1% | -50.3% | ||
| Q1 25 | -30.2% | -53.3% | ||
| Q4 24 | -30.9% | -62.6% | ||
| Q3 24 | -56.9% | -66.6% | ||
| Q2 24 | -72.4% | -76.0% | ||
| Q1 24 | -80.8% | -80.7% |
净利率AMBAZLAB
| Q4 25 | -13.9% | — | ||
| Q3 25 | -20.9% | -31.2% | ||
| Q2 25 | -28.3% | -37.3% | ||
| Q1 25 | -24.1% | -45.8% | ||
| Q4 24 | -29.1% | — | ||
| Q3 24 | -54.8% | -40.9% | ||
| Q2 24 | -69.6% | -80.2% | ||
| Q1 24 | -117.4% | -61.4% |
每股收益（稀释后）AMBAZLAB
| Q4 25 | $-0.35 | $-0.05 | ||
| Q3 25 | $-0.47 | $-0.03 | ||
| Q2 25 | $-0.58 | $-0.04 | ||
| Q1 25 | $-0.48 | $-0.04 | ||
| Q4 24 | $-0.58 | $-0.09 | ||
| Q3 24 | $-0.85 | $-0.04 | ||
| Q2 24 | $-0.93 | $-0.08 | ||
| Q1 24 | $-1.51 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $174.1M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $590.1M | $715.5M |
| 总资产 | $751.9M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMBAZLAB
| Q4 25 | $174.1M | $689.6M | ||
| Q3 25 | $142.7M | $717.2M | ||
| Q2 25 | $141.3M | $732.2M | ||
| Q1 25 | $144.6M | $757.3M | ||
| Q4 24 | $127.1M | $779.7M | ||
| Q3 24 | $153.9M | $616.1M | ||
| Q2 24 | $131.8M | $630.0M | ||
| Q1 24 | $144.9M | $650.8M |
股东权益AMBAZLAB
| Q4 25 | $590.1M | $715.5M | ||
| Q3 25 | $576.5M | $759.9M | ||
| Q2 25 | $572.7M | $791.7M | ||
| Q1 25 | $561.4M | $810.8M | ||
| Q4 24 | $554.3M | $840.9M | ||
| Q3 24 | $547.6M | $667.7M | ||
| Q2 24 | $555.4M | $704.2M | ||
| Q1 24 | $559.9M | $762.2M |
总资产AMBAZLAB
| Q4 25 | $751.9M | $1.2B | ||
| Q3 25 | $706.4M | $1.2B | ||
| Q2 25 | $701.9M | $1.2B | ||
| Q1 25 | $689.0M | $1.2B | ||
| Q4 24 | $670.8M | $1.2B | ||
| Q3 24 | $650.3M | $985.3M | ||
| Q2 24 | $638.7M | $987.4M | ||
| Q1 24 | $657.7M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $34.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $31.4M | $-26.7M |
| 自由现金流率自由现金流/营收 | 29.0% | -21.0% |
| 资本支出强度资本支出/营收 | 2.7% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $64.3M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流AMBAZLAB
| Q4 25 | $34.3M | $-26.0M | ||
| Q3 25 | $5.5M | $-32.0M | ||
| Q2 25 | $14.8M | $-31.0M | ||
| Q1 25 | $25.4M | $-61.7M | ||
| Q4 24 | $6.6M | $-55.8M | ||
| Q3 24 | $16.7M | $-26.8M | ||
| Q2 24 | $-15.0M | $-42.2M | ||
| Q1 24 | $-4.0M | $-90.1M |
自由现金流AMBAZLAB
| Q4 25 | $31.4M | $-26.7M | ||
| Q3 25 | $1.4M | $-35.0M | ||
| Q2 25 | $10.2M | $-33.9M | ||
| Q1 25 | $21.2M | $-63.2M | ||
| Q4 24 | $4.1M | $-58.4M | ||
| Q3 24 | $14.2M | $-28.2M | ||
| Q2 24 | $-16.1M | $-42.9M | ||
| Q1 24 | $-6.0M | $-91.1M |
自由现金流率AMBAZLAB
| Q4 25 | 29.0% | -21.0% | ||
| Q3 25 | 1.4% | -30.4% | ||
| Q2 25 | 11.9% | -31.1% | ||
| Q1 25 | 25.3% | -59.9% | ||
| Q4 24 | 5.0% | -53.8% | ||
| Q3 24 | 22.2% | -27.7% | ||
| Q2 24 | -29.5% | -42.9% | ||
| Q1 24 | -11.6% | -104.5% |
资本支出强度AMBAZLAB
| Q4 25 | 2.7% | 0.5% | ||
| Q3 25 | 4.3% | 2.6% | ||
| Q2 25 | 5.3% | 2.6% | ||
| Q1 25 | 5.0% | 1.5% | ||
| Q4 24 | 3.0% | 2.4% | ||
| Q3 24 | 4.0% | 1.3% | ||
| Q2 24 | 2.1% | 0.7% | ||
| Q1 24 | 3.7% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMBA
| TW | $76.0M | 70% |
| Asia Pacific Other Than Taiwan | $20.2M | 19% |
| North America Other Than United States | $7.4M | 7% |
| Other | $5.0M | 5% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
